Safety and efficacy of everolimus (RAD) as part of a triple immunosuppressive regimen in de novo cardiac transplant recipients: six-month analysis
2002; Elsevier BV; Volume: 21; Issue: 1 Linguagem: Inglês
10.1016/s1053-2498(01)00435-1
ISSN1557-3117
AutoresHoward J. Eisen, Richard Dorent, Donna Mancini, Hannah A. Valantine, M Viganò, R. Starling, Joan M. Lind, Peter Bernhardt, Kamal Abeywickrama,
Tópico(s)Adenosine and Purinergic Signaling
ResumoA 6-month interim analysis of a multicenter 2-year trial compared the safety and efficacy of Certican™ (RAD), a proliferation signal inhibitor that targets primary causes of chronic rejection, with that of azathioprine (AZA). Both agents were given to de novo heart transplant recipients.
Referência(s)